

DRUG METABOLISM AND DISPOSITION

A Publication of the American Society for Pharmacology and Experimental Therapeutics

August 2012

Vol. 40, No. 8

CONTENTS

SHORT COMMUNICATIONS

The Increased Cellular Uptake and Biliary Excretion of Curcumin by Quercetin: A Possible Role of Albumin Binding Interaction. *Han Gyl Kim, Joo Hyun Lee, Seung Jae Lee, Ju-Hee Oh, Eunji Shin, Young Pyo Jang, and Young-Joo Lee* **1452**

A Novel Method for the Determination of the Site of Glucuronidation by Ion Mobility Spectrometry-Mass Spectrometry. *Atsushi Shimizu, Tomoyuki Ohe, and Masato Chiba* **1456**

Covalent Modification and Time-Dependent Inhibition of Human CYP2E1 by the *meta*-Isomer of Acetaminophen. *John P. Harrelson, Brendan D. Stamper, John D. Chapman, David R. Goodlett, and Sidney D. Nelson* **1460**

ARTICLES

Effect of Gemfibrozil on the Metabolism of Brivaracetam In Vitro and in Human Subjects. *J.-M. Nicolas, H. Chanteux, M. Rosa, S. Watanabe, and A. Stockis* **1466**

Boosting of HIV Protease Inhibitors by Ritonavir in the Intestine: The Relative Role of Cytochrome P450 and P-Glycoprotein Inhibition Based on Caco-2 Monolayers versus In Situ Intestinal Perfusion in Mice. *Nico Holmstock, Pieter Annaert, and Patrick Augustijns* **1473**

Reaction of Homopiperazine with Endogenous Formaldehyde: A Carbon Hydrogen Addition Metabolite/Product Identified in Rat Urine and Blood. *Scott Martin, Eva M. Lenz, Dave Temesi, Martin Wild, and Malcolm R. Clench* **1478**

In Vivo Information-Guided Prediction Approach for Assessing the Risks of Drug-Drug Interactions Associated with Circulating Inhibitory Metabolites. *Zhe-Yi Hu, Robert B. Parker, and S. Casey Laizure* **1487**

Evaluation of the Use of Static and Dynamic Models to Predict Drug-Drug Interaction and Its Associated Variability: Impact on Drug Discovery and

Early Development. *Sheila Annie Peters, Patricia E. Schroeder, Nagdeep Giri, and Hugues Dolgos* **1495**

Down-Regulation of Hepatic CYP3A and CYP2C Mediated Metabolism in Rats with Moderate Chronic Kidney Disease. *Thomas J. Velenosi, Angel Y. N. Fu, Shuhua Luo, Hao Wang, and Bradley L. Urquhart* **1508**

Metabolic Activation of Mefenamic Acid Leading to Mefenamyl-S-Acyl-Glutathione Adduct Formation In Vitro and In Vivo in Rat. *Mark P. Grillo, Michelle Tadano Lohr, and Jill C. M. Wait* **1515**

Physicochemical Property Space of Hepatobiliary Transport and Computational Models for Predicting Rat Biliary Excretion. *Manthena V. S. Varma, George Chang, Yurong Lai, Bo Feng, Ayman F. El-Kattan, John Litchfield, and Theunis C. Goosen* **1527**

Inhibition of P-Glycoprotein Leads to Improved Oral Bioavailability of Compound K, an Anticancer Metabolite of Red Ginseng Extract Produced by Gut Microflora. *Zhen Yang, Jing-Rong Wang, Tao Niu, Song Gao, Taijun Yin, Ming You, Zhi-Hong Jiang, and Ming Hu* **1538**

FcRn Affinity-Pharmacokinetic Relationship of Five Human IgG4 Antibodies Engineered for Improved In Vitro FcRn Binding Properties in Cynomolgus Monkeys. *Amita Datta-Mannan, Chi-Kin Chow, Craig Dickinson, David Driver, Jirong Lu, Derrick R. Wücher, and Victor J. Wroblewski* **1545**

Role of the Intestinal Peptide Transporter PEPT1 in Oseltamivir Absorption: In Vitro and In Vivo Studies. *Agnès Poirier, Sara Belli, Christoph Funk, Michael B. Otteneder, Renée Portmann, Katja Heinig, Eric Prinssen, Stanley E. Lazic, Craig R. Rayner, Gerhard Hoffmann, Thomas Singer, David E. Smith, and Franz Schuler* **1556**

Metabolism of (2*S*)-Pterosin A: Identification of the Phase I and Phase II Metabolites in Rat Urine.

Continued on next page

- Yung-Ping Lee, Feng-Lin Hsu, Jaw-Jou Kang, Chien-Kuang Chen, and Shoei-Sheng Lee* **1566**
- ☐ Effect of Structural Variation on Aldehyde Oxidase-Catalyzed Oxidation of Zoniporide. *Deepak Dalvie, Hao Sun, Cathie Xiang, Qiyue Hu, Ying Jiang, and Ping Kang* **1575**
- ☐ Potent Inhibition of Human Sulfotransferase 1A1 by 17 α -Ethinylestradiol: Role of 3'-Phosphoadenosine 5'-Phosphosulfate Binding and Structural Rearrangements in Regulating Inhibition and Activity. *Katie Jo Rohn, Ian T. Cook, Thomas S. Leyh, Susan A. Kadlubar, and Charles N. Falany* . . . **1588**
- Utility of Drug Depletion-Time Profiles in Isolated Hepatocytes for Accessing Hepatic Uptake Clearance: Identifying Rate-Limiting Steps and Role of Passive Processes. *Emilie Jigorel and J. Brian Houston* **1596**
- Expression Profiles of Metabolic Enzymes and Drug Transporters in the Liver and along the Intestine of Beagle Dogs. *Stephanie Haller, Franz Schuler, Stanley E. Lazic, Dalila Bachir-Cherif, Stefanie D. Krämer, Neil J. Parrott, Guido Steiner, and Sara Belli* **1603**
- Brain Distribution and Bioavailability of Elacridar after Different Routes of Administration in the Mouse. *Ramola Sane, Sagar Agarwal, and William F. Elmquist* **1612**
- Preparation of a Specific Monoclonal Antibody against Human UDP-Glucuronosyltransferase (UGT) 1A9 and Evaluation of UGT1A9 Protein Levels in Human Tissues. *Shingo Oda, Miki Nakajima, Masahiko Hatakeyama, Tatsuki Fukami, and Tsuyoshi Yokoi* **1620**
- ☐ Identification of the *ortho*-Benzoquinone Intermediate of 5-*O*-Caffeoylquinic Acid In Vitro and In Vivo: Comparison of Bioactivation under Normal and Pathological Situations. *Cen Xie, Dafang Zhong, and Xiaoyan Chen* **1628**
- ☐ The Development, Characterization, and Application of an OATP1B1 Inhibition Assay in Drug Discovery. *Matthew G. Soars, Patrick Barton, Manfred Ismail, Rachael Jupp, and Robert J. Riley* **1641**

☐ Supplemental material is available online at <http://dmd.aspetjournals.org>.

About the cover: Docking of zoniporide in the homology model of human AO. Human AO was modeled using the crystal structure of bovine XDH as a template. See article by Dalvie et al. on page 1575 of this issue.